Cullinan Therapeutics, Inc. (CGEM) Form 8-K — Aug 6, 2026
Cullinan Therapeutics reported a second-quarter net loss of $53.7 million, a 29% improvement from the prior year period, driven by a 27% reduction in research and development expenses to $44.4 million. The company ended the quarter with $356 million in cash and investments, providing a runway into 2029 under its current operating plan.
Key figures
- Net Loss
- (53,704)
- Ga Expenses
- 12,817
- Rd Expenses
- 44,437
- Total Assets
- 363,787
- Cash Position
- 355,967
- Total Liabilities
- 42,033
- Weighted Average Shares
- 61,493
- Total Current Liabilities
- 40,628
- Total Stockholders Equity
- 321,754
- Basic Diluted Net Loss Per Share
- (0.81)
Price after filing
1 day: +0.3%7 days: +11.9%30 days: +25.9%
Close on the filing date to close N calendar days later (from $17.55). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.